Cost-Effectiveness Analysis of Tisagenlecleucel, Blinatumomab, and Clofarabine for Treatment of B-cell Precursor Acute Lymphoblastic Leukemia | Zendy

AI Assistant Blog Pricing

Open Access

Cost-Effectiveness Analysis of Tisagenlecleucel, Blinatumomab, and Clofarabine for Treatment of B-cell Precursor Acute Lymphoblastic Leukemia

Author(s) -

Kamron Lotfi

Publication year - 2021

Language(s) - English

Resource type - Dissertations/theses

DOI - 10.36837/chapman.000294

Subject(s) - blinatumomab , clofarabine , lymphoblastic leukemia , medicine , refractory (planetary science) , oncology , leukemia , cytarabine , biology , astrobiology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.